HUTCHMED (China) Limited
HCM
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in HongKong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and renal cell carcinoma, colorectal cancer (CRC), and gastriā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
9 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$13.58
Price-1.44%
-$0.20
1Y
Price
Market Cap
$2.379b
Mid
Price/Earnings 3y Avg5y Avg
5.1x
Premium
Premium
Financials Overview
Key metrics over the past few years+0.9%
EBITDA Margin+163.8%
Net Profit Margin-29.6%
Free Cash Flow MarginRevenue
$602.197m
-4.4%
1y CAGR+22.4%
3y CAGR+21.8%
5y CAGREarnings
$466.882m
+1137.5%
1y CAGR+400.9%
3y CAGR+279.4%
5y CAGREPS
$2.65
+1104.6%
1y CAGR+389.7%
3y CAGR+274.3%
5y CAGRBook Value
$1.242b
$1.776b
Assets$534.017m
Liabilities$93.444m
DebtDebt to Assets
5.3%
-12.5x
Debt to EBITDAFree Cash Flow
-$49.657m
-184.8%
1y CAGR-44.3%
3y CAGR-42.8%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company